Chimigen ® Technology-Based Molecular Vaccines

1. Akshaya Bio Inc. Chimigen® Technology-Based Molecular Vaccines InnovationScan November, 2013 1

2. Akshaya Bio Inc. Outline • The Company • Management • Research Team • Collaborators • Chimigen® Platform Technology • Unique Features • Product Pipeline • Status • Highlights • Contacts

3. Akshaya Bio Inc.- Current • Based in Edmonton, Alberta • 8223 Roper Road • Currently a team of Nine, Eight Researchers (7 Ph.Ds, 1 B.Sc. 1 MBA) • Founded in 2010 • Dendritic cell receptor-targeted vaccines • Proprietary technology • 16 issued patents • 32 patents pending worldwide • Acquired Chimigen® Technology from Paladin Labs Inc. and ViRexx Medical Corp., (TSX, AMEX) • External Partners in Research and Development • NRC-IRAP, CHTD, AITF, Gates Foundation • Unique technology platform • Improved antigen presentation • Rich Product Pipeline • HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza,

4. Management Team • SatishChandran, Ph.D • Chief Executive Officer • Rajan George, M.Sc, Ph.D • President and Chief Scientific Officer • Bruce Hirsche, QC • General & Intellectual Property Counsel • Rohit George, BA, MBA • Business Operations

5. Research Team • Allan Ma, Ph.D • Senior Scientist, Virologist • Dakun Wang, Ph.D • Senior Scientist, Immunologist • Yun Xia, Ph.D • Cell Biologist/Immunologist • Morris Kostiuk, Ph.D • Biochemist/Molecular Biologist • Gina Thede, Ph.D • Biochemist/Molecular Biologist • Hue Anh Luu, B.Sc • Technologist

6. Collaborators • NRC/IRAP • Eric Swanson, Ph.D • Nuron Biotech • HBV Vaccine License • HCV Vaccine License Option • University of Alberta- HBV & HCV Clinical Research • Klaus Gutfreund, M.D, Assoc. Professor, Medicine, U of A • Mang Ma, M.D, Assoc. Professor, Medicine, U of A • VIDO/InterVac-Immunology in Animals • Qiang Li, Ph.D • NRC-NINT-Nanoparticles • Nils Peterson, Ph.D • CHTD/Gates Foundation • DRDC Suffield • Les Nagata, Ph.D (Head Biotechnology Section) • NIH • HBV & HCV

7. Chimigen® Platform Technology Novel Approach to an Established ConceptDendritic Cell Receptor-Targeted Vaccines

8. Chimigen®- A Platform Technology Chimigen® Recombinant Molecule Strong Intellectual Property Position 16 Issued Patents, 32 Patent Applications Pending worldwide

9. Chimigen®- A Platform Technology • Characteristics of both Antigen (Ag) and Antibody (Ab) • Xenotypic (foreign) Ab fragment makes whole molecule “foreign” & thus more immunogenic • Adaptable platform • Adaptable to disease-specific multiple molecular antigenic epitopes • HBV, HCV, HIV, Biodefense Applications (Alphaviruses), Pandemic Preparedness (H5N1, H1N1), Malaria, Cancer etc. • Designed to generate broad immune responses • Cellular (Class I)- critical to clear virus infected & cancer cells • Humoral (Class II)- Antibodies • Potential use for both Prophylactic & Therapeutic Vaccines

10. Chimigen®- A Platform Technology • Effective at low doses (µg) • Targets multiple cell types relevant to immune activation • Targets multiple specific receptors on Antigen Presenting Cells • Dendritic Cells (Fcy, Lectin Receptors) • Minimal safety concerns • Utilizes classical antigen presentation pathway • No added adjuvant • Eliminates many adverse events • Eliminates T cell sequestration, dysfunction & deletion (Nat. Med. 2013, Lu. et al) • Ease of production and scalability • Utilizes insect cell-based production • Increased antigenicity through production of the chimeric molecule in Insect Cells • Imparts non-mammalian glycosolation; Highly immunogenic • Established purification systems • Binding and uptake through Fc and Lectin receptors

11. Product Pipeline & Status • HBV Therapeutic/Prophylactic Vaccine • Preclinical completed (Licensed to Nuron, co-development) • HCV Therapeutic/Prophylactic Vaccine • Preclinical (Nuron co-development, option to license) • HIV Prophylactic/Therapeutic Vaccine • Discovery (CHTD-NRC-IRAP) • Cancer Vaccine • Discovery • Malaria • Late discovery stage (Gates Foundation); ready for animal studies • Biodefense and Pandemic Applications • Alphavirus (WEEV) Vaccine, Discovery/Preclinical • Influenza H5 & H1 • Pre-clinical

12. Akshaya’s Competitive Advantages • Meets major unmet needs • No vaccine/therapy available • Efficacy, it works • Proof of Concept established • HBV Chronic Carriers • Breaking Tolerance • No Adjuvant • Eliminates majority of the adverse reactions • The Scare Factor • Eliminates production of “dysfunctional CTLs” • Re-educating the immune system • Uses Dendritic Cell Receptor • Natural endogenous process for uptake and presentation of antigens & induction of broad immune responses

13. Chimigen® Vaccine Highlights Highlights • Versatile, Adaptable Platform • Dendritic Cell Receptor-Targeted Vaccines • Generates broad immune responses • Cellular (Class I)- critical to clear virus infected & cancer cells • Humoral (Class II)- Abs- Helps CTLs • Proof of principle established with Chimigen® HBV Therapeutic Vaccine • Potential use for both Prophylactic & Therapeutic Vaccines • Strong Intellectual Property Position

14. Contacts Rajan George, M.Sc, Ph.D President & Chief Scientific Officer 8223 Roper Road Edmonton Alberta, T6E 6S4 Canada Telephone: 780 989 6705 Mobile: 780 493 1706 Email: rajan.george@akshayabio.com Web: www.akshayabio.com • Satish Chandran, Ph.D • Chief Executive Officer • 8223 Roper Road • Edmonton • Alberta, T6E 6S4 • Canada • Mobile: 215 896 3392 • Email: satish.chandran@akshayabio.com • Web: www.akshayabio.com

15. Akshaya Bio Inc. Thank You…….